Yoshimoto and colleagues reported that engineering B16F10 melanoma cells to express IL-27 substantially increased the number of tumor-infiltrating CD11b+ myeloid cells with expression of M1-type genes including iNOS, IRF8, and Il12p40 and decreased expression of M2-associated markers such as Arg-1, Ym1, and Fizz149,79. This evidence concerns the gene IL27 and melanoma.